Brief: Neuren Pharmaceuticals Says Co To Get $150M from Acadia Pharma's Pediatric Voucher Sale
06/11/2024 01:13
Nov 6 (Reuters) - Neuren Pharmaceuticals NEU.AX :
* ACADIA PHARMACEUTICALS ENTERED INTO AGREEMENT TO SELL RARE
PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR US$150M
* ENTITLED TO RECEIVE ONE-THIRD OF NET PROCEEDS FROM DEAL TO
SELL
RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union